• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

短时间全身输注后5-氟尿嘧啶的药代动力学:分布相结束时的血浆水平作为血浆浓度-时间曲线下总面积的指标。

Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.

作者信息

Port R E, Edler L, Herrmann R, Feldmann U

机构信息

Institute of Biochemistry, Deutsches Krebsforschungszentrum, Heidelberg, F.R.G.

出版信息

Ther Drug Monit. 1991 Mar;13(2):96-102.

PMID:2053130
Abstract

The correlation between single plasma concentration (CP) values of 5-fluorouracil (FU) after a 10-minute i.v. infusion and the total area under the plasma concentration-time curve (AUC) has been studied in 26 cancer patients. FU dose was either 320-550 mg/m2 (seven patients, 13 treatments) or 610-960 mg/m2 (19 patients, 30 treatments). Linear single CP-AUC relationships were found in both dose groups with the CPs at 1, 5, 10, 15, and 30 minutes after the end of infusion. Parameters of linear regression of AUC on single CP differed between the two dose groups. For the high-dose group, the single CPs at repeated treatments were tested as estimators of the total AUC at these treatments, using calibration lines relating total AUC to single CP, which were derived from the data of the first (or only) treatments of all patients. The "best" AUC estimators of the total AUC were the CPs at 10 and 15 minutes after the end of infusion, with a bias of only 2% and an imprecision of only 11% of the AUC values directly determined from the complete concentration-time profiles of the repeated treatments. Because of the close correlation between these single CPs and the total AUC, these CPs should be considered equivalent to the AUC as an overall index of individual FU kinetics after brief infusion of high doses.

摘要

在26例癌症患者中研究了静脉输注10分钟后5-氟尿嘧啶(FU)的单次血浆浓度(CP)值与血浆浓度-时间曲线下总面积(AUC)之间的相关性。FU剂量为320 - 550mg/m²(7例患者,13次治疗)或610 - 960mg/m²(19例患者,30次治疗)。在两个剂量组中均发现输注结束后1、5、10、15和30分钟时的CP与AUC呈线性关系。两个剂量组中AUC对单次CP的线性回归参数有所不同。对于高剂量组,使用将总AUC与单次CP相关联的校准线(这些校准线源自所有患者首次(或仅有的)治疗数据),将重复治疗时的单次CP作为这些治疗中总AUC的估计值进行测试。总AUC的“最佳”AUC估计值是输注结束后10和15分钟时的CP,其偏差仅为2%,不精密度仅为直接从重复治疗的完整浓度-时间曲线确定的AUC值的11%。由于这些单次CP与总AUC之间密切相关,在高剂量短暂输注后,这些CP应被视为等同于AUC,作为个体FU药代动力学的总体指标。

相似文献

1
Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve.短时间全身输注后5-氟尿嘧啶的药代动力学:分布相结束时的血浆水平作为血浆浓度-时间曲线下总面积的指标。
Ther Drug Monit. 1991 Mar;13(2):96-102.
2
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.一项基于药代动力学的试验,用于预防严重的5-氟尿嘧啶毒性。
Clin Pharmacol Ther. 2006 Oct;80(4):384-95. doi: 10.1016/j.clpt.2006.06.007.
3
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.接受持续5-氟尿嘧啶输注的患者与口服尿嘧啶加N1-(2'-四氢呋喃基)-5-氟尿嘧啶患者的5-氟尿嘧啶药代动力学比较。
Clin Cancer Res. 1998 Sep;4(9):2085-8.
4
Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.结直肠癌患者全血、血浆和红细胞中5-氟尿嘧啶药代动力学的比较。
Pharmacotherapy. 1997 Sep-Oct;17(5):881-6.
5
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.对晚期实体瘤患者进行紫杉醇3小时输注后顺铂和5-氟尿嘧啶治疗的I期和药理学研究。
Clin Cancer Res. 1999 Jul;5(7):1723-30.
6
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.癌症患者常规剂量和减少试验剂量后5-氟尿嘧啶及其主要代谢物5-氟-5,6-二氢尿嘧啶的比较药代动力学分析
Clin Cancer Res. 2000 Aug;6(8):3032-7.
7
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.转移性结直肠癌的个体化5-氟尿嘧啶剂量调整:一项使用每两个月一次的药代动力学强化LV5FU2方案的II期研究结果
Cancer Chemother Pharmacol. 2003 Oct;52(4):282-90. doi: 10.1007/s00280-003-0658-0. Epub 2003 Jun 19.
8
Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Cancer Res. 1984 Dec;44(12 Pt 1):5928-33.
9
[Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion].[局部输注5-氟尿嘧啶后大鼠血浆和肝组织中5-氟尿嘧啶的分布]
Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):823-7.
10
5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.5-氟尿嘧啶分剂量给药;晚期结直肠癌中北欧方案不同给药时间表的I/II期及药代动力学研究
Anticancer Res. 2003 Mar-Apr;23(2C):1789-94.

引用本文的文献

1
How may anticancer chemotherapy with fluorouracil be individualised?氟尿嘧啶的抗癌化疗如何实现个体化?
Clin Pharmacokinet. 2006;45(6):567-92. doi: 10.2165/00003088-200645060-00002.
2
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
Br J Cancer. 2002 Apr 8;86(7):1028-33. doi: 10.1038/sj.bjc.6600208.
3
Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.决定晚期结直肠癌患者化疗毒性的危险因素。
Drug Saf. 2000 Oct;23(4):255-78. doi: 10.2165/00002018-200023040-00001.
4
Can pharmacokinetic monitoring improve clinical use of fluorouracil?药代动力学监测能否改善氟尿嘧啶的临床应用?
Clin Pharmacokinet. 1999 Jun;36(6):391-8. doi: 10.2165/00003088-199936060-00001.
5
Limited-sampling models for anticancer agents.抗癌药物的有限采样模型。
J Cancer Res Clin Oncol. 1994;120(7):427-33. doi: 10.1007/BF01240143.